Companies at Leiden Bio Science Park attracted around €350 million in venture capital in 2025. That is significantly more than in previous years. This is according to research by real estate advisor CBRE. Venture capital is money invested in new companies or start-ups in the hope that the value of the shares will increase.
Much more venture capital was raised this year than in previous years. In 2024, companies at Leiden Bio Science Park raised €220 million in venture capital.
Investing in a unique ecosystem
The Wennink Report, published last autumn, underlines the importance of investing in the biotech sector. Targeted investment in red biotechnology leads to a structural GDP boost of 1.2 percentage points, 20,000 additional high-quality jobs, and faster access to innovations for patients. This is according to an economic analysis by KPMG. As a result, red biotechnology, innovative medicines, vaccines, diagnostics, and advanced therapies, can grow into a cornerstone of the Dutch economy.
Leiden Bio Science Park
Leiden Bio Science Park, of which LUMC is part, is the largest Life Sciences & Health cluster in the Netherlands and one of the leading parks in Europe. More than 500 organisations work here every day on new solutions for the health of tomorrow. From start-up to multinational, and from research to large-scale production. The cluster brings companies and knowledge institutions together in one location, creating a strong culture of collaboration. The unique combination of education, research, and business activity makes the area attractive to talent from both the Netherlands and abroad.
With this concentration of knowledge and facilities, Leiden has developed into a place where innovations can reach patients more quickly and where new companies can grow into major players.
